Shopping Cart
Remove All
Your shopping cart is currently empty
Sulesomab
Copy Product Info
🥰Excellent
Synonyms:
Catalog No. T81070 Copy Product Info
🥰Excellent
Sulesomab (IMMU-MN3), an IgG1 class murine monoclonal antibody fragment, targets the Normal Cross-Reactive Antigen-90 found on leukocytes. The compound nonspecifically accumulates at infection sites due to enhanced permeability of capillary membranes [1].
Sulesomab
Cas No. 167747-19-5
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | Inquiry | 4-6 weeks | 4-6 weeks | |
| 5 mg | Inquiry | 4-6 weeks | 4-6 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Storage & Solubility Information
| Description | Sulesomab (IMMU-MN3), an IgG1 class murine monoclonal antibody fragment, targets the Normal Cross-Reactive Antigen-90 found on leukocytes. The compound nonspecifically accumulates at infection sites due to enhanced permeability of capillary membranes [1]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | CEACAM6 |
| Cas No. | 167747-19-5 |
| Storage | -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Preview
Related Tags:
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.